Literature DB >> 18519636

DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Wen Xue1, Alexander Krasnitz, Robert Lucito, Raffaella Sordella, Linda Vanaelst, Carlos Cordon-Cardo, Stephan Singer, Florian Kuehnel, Michael Wigler, Scott Powers, Lars Zender, Scott W Lowe.   

Abstract

Deletions on chromosome 8p are common in human tumors, suggesting that one or more tumor suppressor genes reside in this region. Deleted in Liver Cancer 1 (DLC1) encodes a Rho-GTPase activating protein and is a candidate 8p tumor suppressor. We show that DLC1 knockdown cooperates with Myc to promote hepatocellular carcinoma in mice, and that reintroduction of wild-type DLC1 into hepatoma cells with low DLC1 levels suppresses tumor growth in situ. Cells with reduced DLC1 protein contain increased GTP-bound RhoA, and enforced expression a constitutively activated RhoA allele mimics DLC1 loss in promoting hepatocellular carcinogenesis. Conversely, down-regulation of RhoA selectively inhibits tumor growth of hepatoma cells with disabled DLC1. Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA pathway that may be targeted therapeutically.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519636      PMCID: PMC2418580          DOI: 10.1101/gad.1672608

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  37 in total

Review 1.  The role of Rho GTPases in disease development.

Authors:  Benjamin Boettner; Linda Van Aelst
Journal:  Gene       Date:  2002-03-20       Impact factor: 3.688

2.  Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas.

Authors:  Jianming Ying; Hongyu Li; Paul Murray; Zifen Gao; Yun-Wen Chen; Yajun Wang; Kwan Yeung Lee; Anthony T C Chan; Richard F Ambinder; Gopesh Srivastava; Qian Tao
Journal:  Epigenetics       Date:  2007-01-15       Impact factor: 4.528

3.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.

Authors:  B L Pike; T C Greiner; X Wang; D D Weisenburger; Y-H Hsu; G Renaud; T G Wolfsberg; M Kim; D J Weisenberger; K D Siegmund; W Ye; S Groshen; R Mehrian-Shai; J Delabie; W C Chan; P W Laird; J G Hacia
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

4.  Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.

Authors:  H Matsuyama; Y Pan; K Oba; S Yoshihiro; K Matsuda; L Hägarth; D Kudren; K Naito; U S Bergerheim; P Ekman
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

5.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

Review 6.  TP53 and liver carcinogenesis.

Authors:  Frank Staib; S Perwez Hussain; Lorne J Hofseth; Xin W Wang; Curtis C Harris
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.

Authors:  Bao-Zhu Yuan; Xiaoling Zhou; Marian E Durkin; Drazen B Zimonjic; Katrin Gumundsdottir; Jorunn E Eyfjord; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

8.  DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.

Authors:  Kevin D Healy; Louis Hodgson; Tai-Young Kim; Adam Shutes; Savitri Maddileti; Rudolph L Juliano; Klaus M Hahn; T Kendall Harden; Yung-Jue Bang; Channing J Der
Journal:  Mol Carcinog       Date:  2008-05       Impact factor: 4.784

Review 9.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more
  95 in total

1.  Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.

Authors:  Xuan Cao; Courtney Voss; Bing Zhao; Tomonori Kaneko; Shawn Shun-Cheng Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Solution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.

Authors:  Lihong Chen; Changdong Liu; Frankie Chi Fat Ko; Naining Xu; Irene Oi-Lin Ng; Judy Wai Ping Yam; Guang Zhu
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.

Authors:  Pratima Basak; Rachelle Dillon; Heather Leslie; Afshin Raouf; Michael R A Mowat
Journal:  BMC Cancer       Date:  2015-09-09       Impact factor: 4.430

4.  Mouse models of cancer as biological filters for complex genomic data.

Authors:  Elisa Oricchio; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Hans-Guido Wendel
Journal:  Dis Model Mech       Date:  2010-09-27       Impact factor: 5.758

5.  Target inference from collections of genomic intervals.

Authors:  Alexander Krasnitz; Guoli Sun; Peter Andrews; Michael Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

6.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

Review 7.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

8.  DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.

Authors:  Xuyu Yang; Nicholas C Popescu; Drazen B Zimonjic
Journal:  Cancer Res       Date:  2011-03-03       Impact factor: 12.701

Review 9.  Deregulation of cell signaling in cancer.

Authors:  Filippo G Giancotti
Journal:  FEBS Lett       Date:  2014-02-20       Impact factor: 4.124

10.  A novel approach to tag and identify geranylgeranylated proteins.

Authors:  Lai N Chan; Courtenay Hart; Lea Guo; Tamara Nyberg; Brandon S J Davies; Loren G Fong; Stephen G Young; Brian J Agnew; Fuyuhiko Tamanoi
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.